Ng Lui, Yu Wing Shan, Aung Nilar Myat, Leung Pauline, Luk John Moon, Wong Dennis Anthony, Sun Stella, Foo Dominic Chi-Chung
Department of Surgery, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.
Tiberias Technology (HK) Limited, Shatin, Hong Kong SAR, China.
Cancer Rep (Hoboken). 2024 Dec;7(12):e70069. doi: 10.1002/cnr2.70069.
Colorectal cancer (CRC) is a commonly diagnosed malignancy with significant mortality rates worldwide. The identification of robust prognostic biomarkers for prediction of survival outcomes and recurrence can aid disease management and improve patients' quality of living.
This study aimed to investigate the prognostic value of cadherin 17 (CDH17) tissue expression in CRC patients by utilizing a standardized automated immunohistochemistry (IHC) platform integrated with a digitalized scoring system.
IHC was conducted to assess CDH17 expression on tumor tissues obtained from 150 retrospective CRC cases. A computer-assisted imaging analysis was performed to quantify CDH17 tissue expression using an IHC scoring algorithm known as the Membrane (M) Score. The relationship between CDH17 M Score and clinicopathological factors such as TNM staging, distant metastasis, and recurrence status was analyzed. The prognostic value of CDH17 M Score was determined by Kaplan-Meier curves and Cox regression analysis for overall survival (OS) and recurrence-free survival (RFS). Comparison of M Score and pathologist visual scoring was made to assess the validity of software-derived IHC scoring. CDH17 expression, as measured by M Score, was found to be significantly increased in tumor tissues compared to adjacent normal tissues, and its expression is associated with advanced staging and distant metastasis (normal vs. tumor, p = 0.0011; Stages IV vs. I-III, p < 0.0162; with vs. without metastasis, p = 0.0026; Mann-Whitney U test). Prognostic analysis revealed that high CDH17 M Score was associated with poor OS and RFS (OS, p = 0.0118; RFS, p = 0.0021; log-rank test). Furthermore, multivariate Cox regression analysis identified that CDH17 M Score was an independent prognostic predictor for OS (HR = 2.296, 95% CI = 1.154-4.968, p = 0.0240) and RFS (HR = 2.489, 95% CI = 1.062-6.494, p = 0.0447).
Increased CDH17 M Score was associated with advanced tumor staging and poor survival outcomes using an automated IHC system integrated with a digital image analysis software, highlighting CDH17 could serve as an independent prognostic marker for CRC patients.
结直肠癌（CRC）是一种常见的恶性肿瘤，在全球范围内具有较高的死亡率。识别用于预测生存结果和复发的可靠预后生物标志物有助于疾病管理并提高患者的生活质量。
本研究旨在通过利用标准化的自动化免疫组织化学（IHC）平台结合数字化评分系统，探讨钙黏蛋白17（CDH17）组织表达在CRC患者中的预后价值。
对150例回顾性CRC病例的肿瘤组织进行IHC检测以评估CDH17表达。使用一种称为膜（M）评分的IHC评分算法进行计算机辅助成像分析，以量化CDH17组织表达。分析CDH17 M评分与TNM分期、远处转移和复发状态等临床病理因素之间的关系。通过Kaplan-Meier曲线和Cox回归分析确定CDH17 M评分对总生存期（OS）和无复发生存期（RFS）的预后价值。比较M评分和病理学家的视觉评分以评估软件衍生的IHC评分的有效性。与相邻正常组织相比，通过M评分测量发现肿瘤组织中CDH17表达显著增加，其表达与晚期分期和远处转移相关（正常组织与肿瘤组织，p = 0.0011；IV期与I-III期，p < 0.0162；有转移与无转移，p = 0.0026；Mann-Whitney U检验）。预后分析显示，高CDH17 M评分与较差的OS和RFS相关（OS，p = 0.0118；RFS，p = 0.0021；对数秩检验）。此外，多变量Cox回归分析确定CDH17 M评分是OS（HR = 2.296，95% CI = 1.154 - 4.968，p = 0.0240）和RFS（HR = 2.489，95% CI = 1.062 - 6.494，p = 0.0447）的独立预后预测指标。
使用结合数字图像分析软件的自动化IHC系统，CDH17 M评分增加与肿瘤晚期分期和较差的生存结果相关，突出表明CDH17可作为CRC患者的独立预后标志物。
